INTRODUCTION
Recent advances have clarified the origin of dendritic cells (DCs), a hematopoietic lineage specialized to present antigens and both initiate and control immunity (Heath and Carbone, 2009; Melief, 2008) . In the bone marrow, a common monocyte-DC precursor (Fogg et al., 2006) gives rise to monocytes and other precursors termed common DC precursors Onai et al., 2007) and pre-cDCs ). The latter express intermediate levels of CD11c integrin and begin to synthesize MHC II products. Pre-cDCs move into the blood to seed both lymphoid and nonlymphoid tissues forming CD11c hi , MHC II hi DCs Ginhoux et al., 2009) . DCs in the steady state are dependent upon the hematopoietin, Flt3-L (D' Amico and Wu, 2003) , whereas monocytes require macrophage colony-stimulating factor (M-CSF) (Geissmann et al., 2010) . Flt3-L À/À mice have a severe deficit of DCs Onai et al., 2007; Liu et al., 2009; Waskow et al., 2008) , whereas monocytes are missing in mice lacking M-CSF receptor (c-fms or CD115) (Heard et al., 1987; Ginhoux et al., 2006) . Thus, most DCs in the steady state are independent of monocytes. Nevertheless, monocytes also can differentiate into DCs. Although first studied as macrophage precursors, mainly in vitro (de Villiers et al., 1994; Johnson et al., 1977) , monocytes were later recognized to have an added potential to develop into DCs (monocyte-derived DCs [Mo-DCs] ). This too has been studied primarily in cultures of human blood monocytes (Romani et al., 1994; Sallusto and Lanzavecchia, 1994) . Monocytes, upon culture for several days in GM-CSF and IL-4, acquire a typical probing or dendritic morphology, lose the capacity to phagocytose, and adhere to various tissue culture surfaces but acquire strong capacities to initiate immunity. Mo-DCs can immunize humans (Dhodapkar et al., 1999; Schuler-Thurner et al., 2000) and home to the T cell areas of lymph nodes (LNs) (De Vries et al., 2003) . Monocytes are $20 times more abundant than DCs in blood and marrow, so the mobilization of this monocyte reservoir in vivo to generate potent antigen-presenting DCs needs to be elucidated.
Several reports have begun to document in mice the differentiation of CD11c À and MHC II À blood monocytes into large numbers of CD11c + MHC II + Mo-DCs during different models, e.g., Leishmania major infection via the skin (Leon et al., 2007) , intravenous infection with Listeria monocytogenes (Serbina et al., 2003) , influenza virus infection via the airway (Nakano et al., 2009) , Aspergillus fumigatus in the lung (Hohl et al., 2009) , T cell-mediated colitis (Siddiqui et al., 2010) , and injection of the adjuvant, alum (Kool et al., 2008) . These Mo-DCs presented protein antigens to TCR transgenic CD4 + T cells and are distinguished from classical DCs by expression of the Gr-1/Ly6C monocyte markers. However, many classical functional features of DCs have not been assessed, including a peculiar probing morphology, localization to T cell areas of lymphoid organs in a position to find and activate rare clones of specific T cells, and efficient antigen capture and processing. The latter includes the capacity for cross-presentation. This is the processing of captured proteins onto MHC I without the need for synthesis in antigen-presenting cells (APCs) (Heath and Carbone, 2001) . Through cross-presentation to CD8 + T cells, DCs present nonreplicating antigens, e.g., from dying cells (Liu et al., 2002; Luckashenak et al., 2008) , noninfectious microbes (Moron et al., 2003) , and immune complexes (Regnault et al., 1999) . The CD8 + subset of classical DCs are specialized for cross-presentation (den Haan et al., 2000; Schnorrer et al., 2006; Dudziak et al., 2007; Sancho et al., 2009 ), but Mo-DCs have not been assessed in vivo.
To address these gaps, markers are required to identify Mo-DCs. Here we describe a unique approach using recently isolated monoclonal anti-DC-SIGN/CD209a antibodies (Cheong et al., 2010) . We had previously defined in mice the DC-SIGN or CD209a gene syntenic with human DC-SIGN/CD209 (Park et al., 2001) . DC-SIGN is a hallmark of human Mo-DCs in culture (Geijtenbeek et al., 2000b) but is not detected on the rich network of presumably monocyte-independent DCs in human LNs in the steady state (Granelli-Piperno et al., 2005) . We now find that anti-mouse DC-SIGN/CD209a monoclonal antibodies (mAbs) distinguish Mo-DCs from classical DCs in cell suspensions and tissue sections. We will report that the full differentiation of monocytes to DC-SIGN/CD209a + Mo-DCs does occur in vivo and can be initiated by lipopolysaccharide (LPS) or LPS-expressing bacteria. In contrast to prior reports on inflammatory monocytes, these Mo-DCs rapidly lose expression of monocyte markers Gr-1/Ly6C and CD115/c-fms, markedly upregulate expression of TLR4 and CD14, acquire the probing morphology of DCs, localize to the T cell areas, and through Trif signaling become powerful antigen-capturing and -presenting cells, including cross-presentation of gram-negative bacteria. Naik et al., 2006) with two cytokines, GM-CSF and IL-4, as described for blood monocytes (Schreurs et al., 1999) . After 4-7 days, we recovered $80% of the plated cells. Most had converted to large nonadherent cells that extended and retracted sheet-like processes in several directions from the cell body ( Figure 1A , left), which is the hallmark, probing morphology of DCs (Steinman and Cohn, 1973; Lindquist et al., 2004) . A polyclonal Ab to mouse DC-SIGN detected low levels of the 30 kDa protein in fresh monocytes, but within 2 days of culture, DC-SIGN and MHC II were upregulated markedly ( Figure 1A , right), particularly with IL-4 and GM-CSF in combination, whereas no DC-SIGN was expressed by marrow granulocytes similarly cultured ( Figure S1B ).
RESULTS

DC-SIGN/CD209a Marks
To establish differentiation to DCs, we confirmed that fresh marrow and blood monocytes did not react with mAbs to DC-SIGN, MHC II, or CD11c ( Figure S1B ), but when cultured in GM-CSF and IL-4, strong reactivity developed ( Figure 1B, top) . The combination of GM-CSF and IL-4, but not single cytokines or other hematopoietins like Flt3-L and M-CSF, allowed monocytes to express MHC II and CD11c and develop a DC morphology. When we compared marrow monocytes before and after culture in GM-CSF and IL-4 ( Figure 1C , left, days 0 and 4) to spleen monocytes and classical DCs ( Figure 1C , right panels), we found that Mo-DCs like spleen DCs lacked M-CSF receptor or CD115, a key receptor for monocyte development, whereas both marrow and splenic monocytes expressed CD115 ( Figure 1C ). Splenic but not Mo-DCs expressed Flt3 or CD135 ( Figure 1C ), the receptor for Flt3-L, a major hematopoietin for DCs derived from nonmonocytic precursors.
During differentiation, Mo-DCs also lost the Gr-1 and Ly6C markers of monocytes and reduced their levels of F4/80 but retained high expression of CD11b and CD172a found on both monocytes and DEC-205
spleen DCs ( Figure 1C (Steinman and Witmer, 1978) . In these and all T cell studies, we used CSFE-labeled T cells and monitored the expansion of dividing or CFSE lo cells, as in Figures S1C and S1D. Mo-DCs induced with GM-CSF and IL-4 stimulated a strong MLR, whereas monocytes cultured under other conditions were weak (GM-CSF) or inactive (IL-4, M-CSF, Flt3-L) ( Figure S1C Figure 1D , green).
To compare Mo-DCs with classical DCs that had also been derived from marrow cultures, we used a Flt3-L culture system as described by Naik et al. (2005) (Figure S1E (Sallusto et al., 1995) and DC-SIGN/CD209 (Geijtenbeek et al., 2000b) are induced when cultured human monocytes become Mo-DCs. Using LPS, we observed a 10-fold increase in Figure 2B ). To determine whether Mo-DCs localize to T cell areas like authentic DCs, we used new anti-DC-SIGN mAbs (Cheong et al., 2010) but not LPS-lacking B. subtilis by these routes ( Figure 2C ) or Listeria monocytogenes s.c. (not shown).
To determine if DC-SIGN + cells were distinct from DCs and macrophages in the lymph node, we double-labeled for DC-SIGN and several markers. In PBS-injected mice, the few DC-SIGN + cells were distinct from macrophages in subcapsular and medullary regions of lymph node, which in steady state express CD206 ( Figure 2D ) and SIGN-R1/CD209b ( Figure S2 ). However, in LPS-injected mice, there was a major expansion of cells in the T cell area expressing both CD206 and DC-SIGN/ CD209a ( Figure 2D and Figure S2 ). The DC-SIGN + cells mobilized to the T cell areas by LPS were clearly distinct from other DCs, which expressed higher levels of CD11c, as well as DEC-205/CD205 and Langerin/CD207 (Figure 2E and Figure S2) . Also, DC-SIGN + cells did not colabel with markers that are abundant on lymph node macrophages, such as SIGN-R1/ CD209b and CD169 ( Figure 2E , right panels and Figure S2 ) and F4/80 (not shown). DC-SIGN/CD209a + Mo-DCs also lacked CD115 and Ly6C found on monocytes and inflammatory monocytes (Geissmann et al., 2003) (not shown). Therefore, DC-SIGN marks abundant cells in the T cell areas from LPS-treated mice, which express molecules distinct from classical DCs, macrophages, and monocytes.
Mo-DCs Can Be Selectively Labeled with Injected Anti-DC-SIGN/CD209a Antibody and Isolated from Classical DCs in Lymph Nodes
To compare the properties of LPS-mobilized DC-SIGN + cells to other DCs in LNs, we needed a strategy to separate the cell types. However, the problem we faced was that most DC-SIGN is inside the cell and not on the cell surface, preventing the separation of cell-surface-labeled DC-SIGN + cells. To overcome this obstacle, during injection of LPS (or PBS controls), we also included 10 mg of Alexa dye-labeled MMD3 anti-DC-SIGN mAb, or isotype-matched control mAb, to allow the DC-SIGN + cells to take up the fluorescent mAb. When we examined sections of the injected LNs ( Figure 3A) , we found that the injected anti-DC-SIGN mAb labeled abundant dendritic profiles in the T cell area, but only if the mice had received LPS. No such profiles were seen if we injected isotype control mAb, or if we injected Alexa 488-labeled MMD3 into DC-SIGN À/À mice ( Figure 3A ), which did mobilize numerous macrophage mannose receptor (MMR)/CD206 + cells in response to LPS (Figure 3A and Figure S2E ). The anti-DC-SIGN mAb-targeted cells did not express detectable CD115, but this M-CSF receptor strongly marked lymph node medullary macrophages, and had low levels of CD11c but no DEC-205, which were expressed by classical DCs in the lymph node (not shown).
Therefore to isolate Mo-DCs, we injected LPS together with labeled MMD3 mAb (or isotype control mAb) and made cell suspensions. To identify DCs, we gated on lymphocyte lineage-negative, CD11c
+ cells, and we surface labeled for DEC-205 on cross-presenting classical DCs. In LNs from mice injected with LPS plus-labeled MMD3 mAb, there was a specifically stained DC-SIGN + population, as there was no staining if isotype control mAb was injected ( Figure 3B ), or if we studied DC-SIGN À/À mice ( Figure S3A ). Labeling with MMD3 was comparable in wild-type (WT) and Fc receptor g À/À mice, further indicating that labeling required DC-SIGN and was not Fc mediated ( Figure S3B ). The CD11c + lymphocyte-negative cells also had DEC-205 + and DEC-205 À populations, both lacking DC-SIGN.
Thus LNs from LPS-treated mice have three populations: population #1 corresponds to DC-SIGN/CD209a + DCs, which we will show derive from monocytes, whereas populations #2 and #3 correspond to DEC-205 + (including CD8 + , Figure S3A) and DEC-205 À resident DCs (Vremec and Shortman, 1997) ( Figure 3B and Figures S3A and S3B ). When tested for surface markers following cell sorting, all three populations of DCs from LPS-treated LNs expressed high levels of MHC II, which is expected of DCs, and all expressed CD40, 80, and 86 with the DC-SIGN + and DEC-205 + subsets having the highest levels ( Figure 3C ). However, the DC-SIGN + population had lower levels of CD11c (not shown). We also verified that the sorted DC-SIGN + cells had the probing morphology of DCs ( Figure 3D and Movie S1 for video). All three DC populations likewise failed to stain for CD115/c-fms, but DC-SIGN + cells lacked CD135/Flt3, which was expressed by lymph node resident DCs ( Figure 3E Figure 3F and Figure S3C ). Figure 4A ).
To establish the monocyte origin of LPS-recruited Mo-DCs by an alternative method, we focused on LysMcre 3 iDTR mice, in which treatment with diphtheria toxin (DT) depletes monocytes and macrophages (Goren et al., 2009) . We confirmed that a single dose of DT i.v. decreased >80% of blood monocytes 12 hr later ( Figure 4B ). DT-treated, LPS-injected WT mice generated CD11c + DC-SIGN + cells normally ( Figure 4B , right, arrow), but DT-treated, LPS-injected LysMcre 3 iDTR mice failed to generate Mo-DCs, although the classical monocyte-independent DC subsets were normally represented ( Figure 4B, right) . Likewise in tissue sections, DC-SIGN + DCs were not recruited into the T cell areas of LNs of LPS-treated LysMcre 3 iDTR mice upon DT treatment, but DEC-205 + DCs were abundant in LPS-and DT-treated WT and LysMcre 3 iDTR mice ( Figure 4C , green versus red), again showing that Mo-DCs derived from monocytes, whereas classical DCs did not. To test whether the spleen was needed, a recently recognized source of monocytes (Swirski et al., 2009 ), we studied splenectomized mice. However after LPS injection, these mice normally mobilized DC-SIGN/CD209a + MMR/CD206 + Mo-DCs ( Figure S4A ).
To selectively deplete classical DCs, we employed Flt3
mice, which lack classical DCs because of a need for Flt3 signaling. We confirmed a loss of classical DCs in Flt3 À/À mice (Waskow et al., 2008) , but in contrast, LPS comparably mobilized Mo-DCs from Flt3 À/À and WT mice using either DC-SIGN/ CD209a or MMR/CD206 as markers ( Figure 4D and Figure S4B) . To determine whether cell proliferation was involved, we labeled mice with BrdU during the 12 hr treatment with LPS, but no labeling was evident in contrast to the basal level of BrdU labeling of classical DCs ( Figure S4C ). These results provide considerable evidence for the monocyte origin of DC-SIGN Figure S3C ).
L-Selectin and CCR7 Are Required for LPS to Generate Mo-DCs
To begin to identify mechanisms of Mo-DC mobilization, we evaluated the lymph node homing molecule used by lymphocytes, L-selectin/CD62L, which is also expressed on monocytes prior to their becoming Mo-DCs (e.g., in Figure 1C ). We treated mice with isotype control or anti-CD62L (MEL-14) mAb and 1 hr later injected LPS. Anti-CD62L blocked Mo-DC formation in LNs using immunolabeling of sections and cell suspensions ( Figures 5A and 5B) . To identify the required chemokine receptors, we tested four chemokine receptor knockout mice. Accumulation of DC-SIGN + Mo-DCs was critically dependent on CCR7 (Figure 5C, right) . Only a partial but statistically significant decrease in Mo-DCs was noted in CCR2 À/À mice ( Figure S5A ), whereas CCR5 and CCR6 were not necessary ( Figure 5C ). Monocytes disappeared normally from the blood in LPS-treated CCR7
À/À mice, and CCR7 was not required to generate Mo-DCs in vitro ( Figures S5B and S5C) . In all these experiments, we verified that spleen DCs in the knockout mice responded normally to LPS by upregulating CD86 ( Figure 5C , right). To establish that the need for CCR7 was cell intrinsic, we made mixed bone marrow chimeras with 50:50 mixes of WT and CCR7 À/À donor cells, each marked with CD45.1 and CD45.2 and injected into CD45.1 + WT hosts. Six weeks later, we certified chimerism in the blood ( Figure 5D , left) and injected LPS to recruit DC-SIGN/CD209a + MMR/CD206 + DCs. LPS greatly reduced the number of monocytes in the blood ( Figure 5D , middle), but only Figure 5D , right), indicating that the need for CCR7 by Mo-DCs is cell intrinsic.
Mo-DCs Efficiently Present Proteins and Bacteria Captured In Vivo to T Cells
To test the antigen-presenting functions of Mo-DCs, we initially sorted three populations of CD11c hi DCs from inflamed LNs using CD11c, DEC-205, and DC-SIGN as markers as in Figure 3B . All three DC types from LPS-treated mice effectively stimulated allogeneic T cells in the MLR assay, with Mo-DCs being moderately more active ( Figure 6A , left and Figure S6) . Surprisingly, Mo-DCs were comparable or superior to classical DCs in presenting two different proteins (OVA, which is glycosylated, and CSP, which is nonglycosylated) to CD8 + and CD4 + TCR transgenic T cells ( Figure 6A ). Thus just like the Mo-DCs that can be generated in culture by adding GM-CSF and IL-4 to monocytes, LPS-mobilized Mo-DCs in vivo are as good or better presenting cells than classical DCs, including cross-presentation. Figure 6B and Figure S6 ), showing that these cells capture and present on both MHC I and II in vivo. To determine the type of T cell that was developing in response to antigen-presenting Mo-DCs, we collected the medium from 4 day cocultures of OT-II CD4 + TCR transgenic T cells with Mo-DCs that had captured OVA in vivo. The Mo-DCs induced strong production of IFN-g and IL-2 but not IL-4, IL-10, or IL-17 ( Figure 6C ), suggesting Th1 differentiation. To evaluate presentation of bacterial antigens, we injected recombinant E. coli OVA (or E. coli control). Twelve hours later, we isolated three populations of DCs from the LNs. Mo-DCs were even more effective than DEC-205 + classical cross-presenting DCs, whereas DEC-205 À DCs did not cross-present bacteria ( Figure 6D ).
Mo-DCs Selectively Express CD14, a Needed Coreceptor for Trif-Dependent LPS Signaling
To begin to understand why LPS and gram-negative bacteria were superior agonists for mobilizing Mo-DCs, we first used quantitative PCR to assess expression of several TLRs in marrow monocytes and Mo-DCs. Both cells expressed several
TLRs, but TLR4 and its coreceptor CD14 were markedly upregulated in Mo-DCs ( Figure 7A ). To pursue the contribution of the LPS coreceptor, CD14, we used monoclonal anti-CD14 to show that monocytes were selectively CD14 + in blood ( Figure S7A ), whereas among CD11c hi DCs in the LNs from LPS-stimulated mice, only DC-SIGN + Mo-DCs were CD14 + ( Figure 7B ). When we studied CD14 À/À mice, which lacked CD14 on monocytes ( Figure S7B ), LPS injection failed to mobilize Mo-DCs ( Figure 7C ). We then compared mice lacking the MyD88 and Trif adaptors for TLR4 signaling, where CD14 is a known coreceptor for MyD88-independent, Trif-dependent signaling (Jiang et al., 2005) . Trif, not MyD88, was essential for LPS to mobilize Mo-DCs ( Figure 7D ) and to upregulate CD86 on splenic DCs ( Figure S7C ). CD14 + DCs accumulated with identical kinetics to DC-SIGN + Mo-DCs, peaking at 24 hr and becoming the dominant DCs in LNs ( Figure 7E and Figure S7D) . Together, the data indicate that CD14, a coreceptor for TLR4, is upregulated by LPS and is essential for Mo-DC differentiation via Trif signaling. To find out if selective expression of CD14 provided an independent means to isolate Mo-DCs after injecting antigens in vivo, we compared CD14 surface labeling to MMD3 in vivo labeling. With either approach, Mo-DCs were similar and superior cross-presenting DCs ( Figure 7E ). Thus monocyte differentiation to DCs in response to LPS requires CD14, which serves as an alternative marker to identify and isolate Mo-DCs from classical DCs.
DISCUSSION
One can use the term ''authentic'' for the Mo-DCs described here for several reasons, which have not previously been noted for inflammatory monocytes. The Mo-DCs are dendritic cells in terms of their motility because they are nonadherent cells that continually form and retract processes in the living state, identical to the probing morphology of DCs in the T cell areas of living LNs (Lindquist et al., 2004) . These Mo-DCs also concentrate in the T cell areas, again a classic feature of DCs and a location that facilitates clonal selection of antigen-specific T cells from the recirculating repertoire. The Mo-DCs are very similar in phenotype to DCs in lymphoid tissues including the loss of markers that were used previously to positively identify inflammatory monocytes in vivo, i.e., Ly6C and Gr-1 antigens and CD115/c-fms receptor.
Importantly, when Mo-DCs are compared functionally to classical DCs from the same LNs, the former are not only active but can be superior in stimulating the MLR and in presenting protein antigens, administered in vitro and also in vivo prior to testing as presenting cells. A large amount of previous emphasis has been A B C D Figure 6 . Presentation of Malaria CS and OVA Proteins by Three Types of DCs (A). C57BL/6 or B6 3 BALB/c F1 mice were injected i.v. with 5 mg LPS for 12 hr to isolate three DC fractions (>95% purity), as in Figure 3B . Graded doses were added with 40 mg/ml protein to 50,000 CFSE-labeled T cells, and 3-4 days later, CFSE lo T cells were counted. An MLR was also run to verify DC activity. placed on the superior cross-presenting activity of the CD8 + or DEC-205 + subset of DCs, but the Mo-DCs we describe can be equally or more effective than CD8 + DCs, including for bacteria injected in vivo. Thus Mo-DCs are equivalent in many functional respects to DCs, except that they are monocyte dependent, whereas numerous prior studies show that classical DCs are monocyte independent (Naik et al., 2006; Varol et al., 2007) and derive from a committed pre-cDC in the bone marrow ). None of these new functional features of Mo-DCs have been described before for monocyte-derived cells in various inflammatory conditions. The finding that permitted our research was the derivation of mAbs to DC-SIGN or CD209a that recognized this lectin in tissue sections, much of which are intracellular in location (Cheong et al., 2010) . The new anti-DC-SIGN/CD209a mAbs allowed us to visualize the LPS-induced mobilization of Mo-DCs in the T cell areas and distinguish them from the resident DCs there. Previously, a combination of CD11b and CD11c markers were used to help identify inflammatory monocytes with some features of DCs (Leon et al., 2007; Serbina et al., 2003; Nakano et al., 2009; Hohl et al., 2009; Siddiqui et al., 2010; Kool et al., 2008) , but these integrins are not sufficient to permit localization in situ, and the Mo-DCs actually have lower levels of CD11c than classical DCs. Previous isolations also used antibodies to Ly6C or Gr-1, but these markers are lost from the Mo-DCs described here. Although DC-SIGN/CD209a was critical for identifying authentic Mo-DCs in vivo, functions for this lectin need research. We showed, for example, that DC-SIGN À/À monocytes become Mo-DCs (marked by MMR/CD206) in the T cell areas, just like WT monocytes, when the mice are given LPS ( Figure S2E ). Therefore DC-SIGN seems not to be involved in Mo-DC mobilization and differentiation. Also Mo-DCs cultured from DC-SIGN À/À mice still present antigens to OT-I and OT-II transgenic T cells comparably to WT (not shown). DC-SIGN/CD209 can play pathogenic roles, either in transmitting infectious agents like HIV and CMV in the case of cultured human Mo-DCs (Geijtenbeek et al., 2000a; Halary et al., 2002) or in transducing inhibitory signals as seen when human DC-SIGN/CD209 interacts with mycobacteria (Geijtenbeek et al., 2003; Tailleux et al., 2003) . DC-SIGN/CD209 could also have protective functions for capture and presentation of glycan-modified antigens (Tacken et al., 2005) . Also the pathway described here to mobilize DC-SIGN/CD209a + DCs could generate new vaccination strategies, given the powerful antigen presentation and immune stimulatory consequences of this full DC differentiation pathway. We have identified one molecular pathway to produce Mo-DCs in vivo, which is rapid differentiation from blood monocytes upon administration of TLR4 agonists to mice. The classical method to produce DC-SIGN/CD209 + MMR/CD206 + Mo-DCs from human (Romani et al., 1994; Sallusto and Lanzavecchia, 1994) and mouse (Schreurs et al., 1999; Agger et al., 2000) blood monocytes takes several days of culture in GM-CSF and IL-4, but here we show that LPS and LPS + live and dead bacteria act rapidly within hours. Blood monocytes drop to 20% of their normal levels 6-12 hr after i.v. LPS, and at the same time, cells move into LNs and differentiate into DC-SIGN/CD209a + MMR/CD206 + Mo-DCs. This influx requires CCR7 and CD62L, both expressed by bone marrow and blood monocytes. Among the agonists for Toll-like receptors that we studied, only LPS via TLR4 had this capacity to induce Mo-DCs. In spite of hundreds of studies of the response of mice to LPS, this mobilization of antigen-presenting cells was not previously appreciated.
To explain the peculiar role of TLR4 agonists, we first examined gene expression for several TLRs. Whereas monocytes expressed many TLRs, only TLR4 increased markedly when monocytes differentiated into Mo-DCs in culture. This was also the case for the CD14 coreceptor for TLR4, which mediates MyD88-independent and Trif-dependent TLR4 signaling (Jiang et al., 2005) . Xu et al. have shown previously that GM-CSF/IL-4-derived DCs produce cytokines in response to several agonists, e.g., Pam3Cys and ODN1826 (Xu et al., 2007) , which we found did not mobilize Mo-DCs from monocytes in vivo. However, a key feature of the Mo-DCs that are mobilized by LPS is that they express CD14, which not only proved to be an independent marker for Mo-DCs but was also essential for their generation.
We would like to propose that the mobilization of Mo-DCs described here has two roles. One is part of the innate response to gram-negative bacteria and other agents that contain agonists for the TLR4-CD14 complex, although this will require additional studies of the functional properties of Mo-DCs such as the production of cytokines and chemokines. A second is as a segue to the adaptive immune response. During the TLR4-based response, Mo-DCs increase while classical DCs decrease, so that Mo-DCs become the dominant cell for induction of effective and combined CD4 + and CD8 + T cell immunity, with or without the requirement for bacterial replication in this newly mobilized DC reservoir. À/À mice were from Jackson Labs and C3H/HeN and splenectomized mice from Taconic Farms. Mice in specific pathogen-free conditions were studied at 6-10 weeks according to institutional guidelines of the Rockefeller University.
Lipopolysaccharide and Bacteria LPS from E. coli 055:B5 (Sigma) was given i.v., s.c., or intraperitoneally (i.p.) at a dose of 5 mg to induce Mo-DCs. For optimal LPS activity, stocks had to be dissolved at 10 mg/ml or higher. Other TLR agonists were purchased from Invivogen and injected i.v. at 5 mg/mouse. We also tested bacteria at a dose of 5 3 10 6 per mouse, both heat-killed and live bacteria (E. coli DH5a, B. subtilis).
To evaluate presentation of proteins from bacteria, recombinant E. coli expressing OVA was used. To generate Mo-DCs, monocytes were cultured with cytokines (M-CSF, GM-CSF, GM-CSF, IL-4; PeproTech) at 20 ng/ml or Flt3-L at 200 ng/ml in RPMI with 5% FBS and antibiotic-antimycotic plus b-mercaptoethanol (Invitrogen). At 4-7 days, nonadherent cells were removed to test function, or for M-CSF, adherent cells were recovered with Cellstripper nonenzymatic cell dissociation solution (Mediatech). Alternatively, to generate DCs, total bone marrow was cultured with Flt3-L (400 ng/ml) for 9 days as described (Naik et al., 2005) , and the equivalents of CD8 + and CD8 À spleen DCs were sorted as CD24 hi CD11b lo and CD24 lo CD11b hi cells, respectively.
Bone Marrow Monocytes and DCs
Monocyte and Bone Marrow Transfer 2 3 10 6 CD45.2 + marrow monocytes were transferred to 4-to 6-week CD45.1 + mice (>8 weeks gave poor results). For mixed marrow chimeras, 50:50 mixtures of knockout (KO) and WT marrow were injected i.v. into lethally irradiated (5.5 Gy twice, 3 hr apart) mice. To deplete monocytes, DT (Sigma) in PBS (1 mg/ml, stored at À80 C) was injected i.v. to LysMcre 3 iDTR mice at 25 ng/g weight ($500 ng/mouse).
Antibodies, Flow Cytometry, and Microscopy
Rabbit polyclonal antibody to a 14 amino acid cytoplasmic domain peptide of DC-SIGN and mAbs to DC-SIGN (BMD10, BMD30, and MMD3) were described (Cheong et al., 2010) . mAbs were conjugated with biotin or Alexa 647 (Invitrogen) following manufacturer's instructions. These bound specifically to CHO cells stably expressing mouse DC-SIGN.
control), and MEL-14 (a-CD62L) mAbs were purified from hybridoma supernatants or purchased from eBioscience, and they were tested to be endotoxin free (QCL-1000 kit, BioWhittaker). We purchased mAbs conjugated to different fluorochromes to CD19, CD3, NK1.1, DX-5, CD206, CD11b, I-A/I-E (MHC II), CD135, CD172a, CD14, and Ly6G from BD Bioscience; MMR/CD206 from Biolegend; PE-a-mouse CD115, CD8a, Gr-1, CD11b, CD40, CD24, Mac-3, CD62L, and CD14 from eBioscience; F4/80 and Ly6C (PE or Alexa 647) from AbD Serotec. For BrdU labeling, 200 ml of 10 mg/ml of BrdU was injected i.p. for 12 hr; staining followed manufacturer's instruction (FITC BrdU flow kit, BD).
Lymph Node Cells and Sections
Skin-draining nodes were treated with collagenase D (400 U/ml) for 30 min at 37 C. Cells were preincubated 10 min with 2.4G2 mAb at 4 C to block Fc receptors, stained with fluorescent mAbs, acquired on a BD-LSRII, and analyzed using flowjo (Treestar 
